Getty Images
- A new class of weight loss drugs are powering massive stock market gains for Novo Nordisk and Eli Lilly.
- Both stocks surged more than 16% on Tuesday, boosting the combined valuation of both companies to nearly $1 trillion.
- A new study showed Novo Nordisk's Wegovy lowered the risk of heart attack or stroke by 20%.
A new class of weight loss drugs has powered massive stock market gains for two pharmaceutical companies: Novo Nordisk and Eli Lilly.